questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-tyrosine kinases
Protein-tyrosine kinases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases
Biopsie
Tests sanguins
Marqueurs tumoraux
Kinases
CA 19-9
Tests génétiques
Mutations
Kinases
Antécédents familiaux
Cancer
Kinases
Symptômes
5
Fatigue
Perte de poids
Kinases
Kinases
Voies de signalisation
Symptômes
Cancers
Masse palpable
Saignements
Fatigue
Maladies
Symptômes
Évolution des symptômes
Surveillance
Kinases
Prévention
5
Prévention
Alimentation saine
Exercice
Dépistage
Anomalies
Kinases
Vaccins
Prévention
Kinases
Tabagisme
Facteurs de risque
Kinases
Facteurs environnementaux
Substances chimiques
Kinases
Traitements
5
Inhibiteurs de kinases
Imatinib
Traitements
Traitements personnalisés
Mutations
Kinases
Effets secondaires
Fatigue
Nausées
Radiothérapie
Traitements ciblés
Kinases
Efficacité des traitements
Rémission
Kinases
Complications
5
Complications
Résistance aux traitements
Progression de la maladie
Complications
Gestion
Kinases
Pronostic
Complications
Rémission
Type de cancer
Complications
Kinases
Traitements supplémentaires
Complications
Kinases
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Tabagisme
Mode de vie
Risque
Kinases
Infections
Virus d'Epstein-Barr
Risque
Facteurs génétiques
Mutations
Kinases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protein-tyrosine kinases : Questions médicales les plus fréquentes",
"headline": "Protein-tyrosine kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protein-tyrosine kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines et peptides de signalisation intracellulaire",
"url": "https://questionsmedicales.fr/mesh/D047908",
"about": {
"@type": "MedicalCondition",
"name": "Protéines et peptides de signalisation intracellulaire",
"code": {
"@type": "MedicalCode",
"code": "D047908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agammaglobulinaemia tyrosine kinase",
"alternateName": "Agammaglobulinaemia Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D000077329",
"about": {
"@type": "MedicalCondition",
"name": "Agammaglobulinaemia tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D000077329",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Focal adhesion protein-tyrosine kinases",
"alternateName": "Focal Adhesion Protein-Tyrosine Kinases",
"url": "https://questionsmedicales.fr/mesh/D051416",
"about": {
"@type": "MedicalCondition",
"name": "Focal adhesion protein-tyrosine kinases",
"code": {
"@type": "MedicalCode",
"code": "D051416",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.049"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinases",
"alternateName": "Janus Kinases",
"url": "https://questionsmedicales.fr/mesh/D053612",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinases",
"code": {
"@type": "MedicalCode",
"code": "D053612",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Janus kinase 1",
"alternateName": "Janus Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D053613",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D053613",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Janus kinase 3",
"alternateName": "Janus Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D053616",
"about": {
"@type": "MedicalCondition",
"name": "Janus kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D053616",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "TYK2 Kinase",
"alternateName": "TYK2 Kinase",
"url": "https://questionsmedicales.fr/mesh/D053634",
"about": {
"@type": "MedicalCondition",
"name": "TYK2 Kinase",
"code": {
"@type": "MedicalCode",
"code": "D053634",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.124.650"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase Kinases",
"alternateName": "Mitogen-Activated Protein Kinase Kinases",
"url": "https://questionsmedicales.fr/mesh/D020929",
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase Kinases",
"code": {
"@type": "MedicalCode",
"code": "D020929",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 1",
"alternateName": "MAP Kinase Kinase 1",
"url": "https://questionsmedicales.fr/mesh/D048369",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 1",
"code": {
"@type": "MedicalCode",
"code": "D048369",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 2",
"alternateName": "MAP Kinase Kinase 2",
"url": "https://questionsmedicales.fr/mesh/D048370",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 2",
"code": {
"@type": "MedicalCode",
"code": "D048370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 3",
"alternateName": "MAP Kinase Kinase 3",
"url": "https://questionsmedicales.fr/mesh/D048371",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 4",
"alternateName": "MAP Kinase Kinase 4",
"url": "https://questionsmedicales.fr/mesh/D048670",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 4",
"code": {
"@type": "MedicalCode",
"code": "D048670",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 5",
"alternateName": "MAP Kinase Kinase 5",
"url": "https://questionsmedicales.fr/mesh/D048671",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 5",
"code": {
"@type": "MedicalCode",
"code": "D048671",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 6",
"alternateName": "MAP Kinase Kinase 6",
"url": "https://questionsmedicales.fr/mesh/D048669",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 6",
"code": {
"@type": "MedicalCode",
"code": "D048669",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "MAP Kinase Kinase 7",
"alternateName": "MAP Kinase Kinase 7",
"url": "https://questionsmedicales.fr/mesh/D048688",
"about": {
"@type": "MedicalCondition",
"name": "MAP Kinase Kinase 7",
"code": {
"@type": "MedicalCode",
"code": "D048688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.200.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Syk kinase",
"alternateName": "Syk Kinase",
"url": "https://questionsmedicales.fr/mesh/D000072377",
"about": {
"@type": "MedicalCondition",
"name": "Syk kinase",
"code": {
"@type": "MedicalCode",
"code": "D000072377",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "src-Family kinases",
"alternateName": "src-Family Kinases",
"url": "https://questionsmedicales.fr/mesh/D019061",
"about": {
"@type": "MedicalCondition",
"name": "src-Family kinases",
"code": {
"@type": "MedicalCode",
"code": "D019061",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "CSK tyrosine-protein kinase",
"alternateName": "CSK Tyrosine-Protein Kinase",
"url": "https://questionsmedicales.fr/mesh/D000081247",
"about": {
"@type": "MedicalCondition",
"name": "CSK tyrosine-protein kinase",
"code": {
"@type": "MedicalCode",
"code": "D000081247",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.800.158"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "ZAP-70 Protein-tyrosine kinase",
"alternateName": "ZAP-70 Protein-Tyrosine Kinase",
"url": "https://questionsmedicales.fr/mesh/D051746",
"about": {
"@type": "MedicalCondition",
"name": "ZAP-70 Protein-tyrosine kinase",
"code": {
"@type": "MedicalCode",
"code": "D051746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.568.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protein-tyrosine kinases",
"alternateName": "Protein-Tyrosine Kinases",
"code": {
"@type": "MedicalCode",
"code": "D011505",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Angela L Tyner",
"url": "https://questionsmedicales.fr/author/Angela%20L%20Tyner",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu."
}
},
{
"@type": "Person",
"name": "Eiji Kinoshita",
"url": "https://questionsmedicales.fr/author/Eiji%20Kinoshita",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Emiko Kinoshita-Kikuta",
"url": "https://questionsmedicales.fr/author/Emiko%20Kinoshita-Kikuta",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Tohru Koike",
"url": "https://questionsmedicales.fr/author/Tohru%20Koike",
"affiliation": {
"@type": "Organization",
"name": "Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan."
}
},
{
"@type": "Person",
"name": "Gongqin Sun",
"url": "https://questionsmedicales.fr/author/Gongqin%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Fluoroscopic Intraoperative Breast Neoplasm and Node Detection.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36728380",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/XCS.0000000000000548"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metastatic primary breast neuroendocrine neoplasms: a case series.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36314732",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/imj.15961"
}
},
{
"@type": "ScholarlyArticle",
"name": "Galectin-3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36125083",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/JLB.5MR0822-673R"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36008514",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-18712-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37473463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2023.112952"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-tyrosine kinases",
"item": "https://questionsmedicales.fr/mesh/D011505"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protein-tyrosine kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protein-tyrosine kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protein-tyrosine kinases",
"description": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?\nQuels marqueurs sont utilisés pour le diagnostic ?\nLes tests génétiques sont-ils utiles ?\nQuels examens d'imagerie sont recommandés ?\nLes antécédents familiaux influencent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Breast+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protein-tyrosine kinases",
"description": "Quels symptômes sont liés à une suractivité des kinases ?\nLes symptômes varient-ils selon le type de kinase ?\nY a-t-il des symptômes spécifiques aux cancers ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Breast+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protein-tyrosine kinases",
"description": "Peut-on prévenir les dysfonctionnements des kinases ?\nLes dépistages réguliers sont-ils recommandés ?\nY a-t-il des vaccins préventifs ?\nLe tabagisme influence-t-il le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Breast+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protein-tyrosine kinases",
"description": "Quels traitements ciblent les kinases à tyrosine ?\nLes traitements sont-ils personnalisés ?\nQuels effets secondaires des traitements sont courants ?\nLa radiothérapie est-elle utilisée ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Breast+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protein-tyrosine kinases",
"description": "Quelles complications peuvent survenir avec les kinases ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nLes complications varient-elles selon le type de cancer ?\nLes complications nécessitent-elles des traitements supplémentaires ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Breast+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protein-tyrosine kinases",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de dysfonctionnement des kinases ?\nLe mode de vie joue-t-il un rôle ?\nLes infections peuvent-elles être un facteur de risque ?\nY a-t-il des facteurs génétiques impliqués ?",
"url": "https://questionsmedicales.fr/mesh/D011505?mesh_terms=Breast+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des kinases à tyrosine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des biopsies peuvent révéler des anomalies dans l'activité des kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs tumoraux comme le CA 19-9 peuvent indiquer une activité kinase anormale."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations dans les gènes codant pour les kinases à tyrosine."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont recommandés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et le scanner peuvent aider à visualiser les tumeurs associées aux kinases."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancers peuvent augmenter le risque de dysrégulation des kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une suractivité des kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, perte de poids, et douleurs osseuses peuvent indiquer une suractivité des kinases."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de kinase ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de kinase et de la voie de signalisation affectée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux cancers ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des masses palpables ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue peuvent être communs à plusieurs maladies."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent s'aggraver progressivement, nécessitant une surveillance régulière."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements des kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et l'exercice régulier peuvent réduire le risque de cancers."
}
},
{
"@type": "Question",
"name": "Les dépistages réguliers sont-ils recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages peuvent aider à détecter précocement des anomalies liées aux kinases."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins préventifs ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les dysfonctionnements des kinases."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour plusieurs cancers liés aux kinases."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances chimiques peut augmenter le risque de dysfonctionnement des kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les kinases à tyrosine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de kinases, comme l'imatinib, sont utilisés pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques des kinases."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des traitements sont courants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, nausées et éruptions cutanées sont des effets secondaires fréquents."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée en complément des traitements ciblés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie, mais certains patients peuvent bénéficier d'une rémission prolongée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la résistance aux traitements et la progression de la maladie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles le pronostic ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent aggraver le pronostic et réduire les chances de rémission."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent différer selon le type de cancer et la kinase impliquée."
}
},
{
"@type": "Question",
"name": "Les complications nécessitent-elles des traitements supplémentaires ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements supplémentaires peuvent être nécessaires pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le tabagisme et l'exposition à des produits chimiques sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dysfonctionnement des kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, surtout pour certains cancers."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques héréditaires peuvent prédisposer à des dysfonctionnements des kinases."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 30/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA; University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: atyner@uic.edu.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Functional Molecular Science, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Publications dans "Protein-tyrosine kinases" :
3 publications dans cette catégorie
Affiliations :
Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, United States.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
University of Massachusetts Chan Medical School, Worcester, United States. Electronic address: swati.jaiswal@umassmed.edu.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Center for Cancer Training, NCI, and Digestive Diseases Branch, NIDDK, NIH, Bethesda, MD 20892, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Life Sciences, Yeongnam University, Gyeongsan, Gyeongbuk 38451, South Korea.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
Publications dans "Protein-tyrosine kinases" :
2 publications dans cette catégorie
Affiliations :
Department of Psychiatry, Weill Cornell Medicine. New York, NY 10065, USA; Department of Biochemistry, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: jtl2003@med.cornell.edu.
Publications dans "Protein-tyrosine kinases" :
Preoperative localization is necessary for nonpalpable breast lesions. A novel procedure, fluoroscopic intraoperative neoplasm and node detection (FIND), obviates the preoperative painful and potentia...
This is an IRB-approved retrospective study (September 2016 to March 2021). Electronic chart review identified breast and axillary node procedures using wire localization (WL) or FIND. Primary outcome...
We identified 459 patients, of whom 116 (25.3%) underwent FIND and 343 (74.7%) WL. Of these, 68.1% of FIND and 72.0% of WL procedures were for malignant lesions. Final margin positivity was 5.1% (4 of...
FIND has lower positive margin rates and a trend towards lower re-excision rates compared with WL, proving its value in localizing nonpalpable breast lesions. It also offers accurate localization of a...
Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting....
To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature....
We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging...
We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011-2021) f...
This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first-line setting, first-line PFS r...
Galectin-3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor micro...
Breast cancer causes morbidity and mortality among women worldwide, despite much research illuminating the genetic basis of this disease. Anti-angiogenesis therapies have been widely studied, although...
Long-term complications are becoming more important as the survival rate of breast cancer improves. Treatment-related myeloid neoplasm is an important long-term complication in breast cancer survivors...
We evaluated the incidence and risk factors for the development of treatment-related acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) in patients treated with early breast cancer....
We accessed the national Korean database to identify 153,565 patients diagnosed with breast cancer between January 2007 and October 2016 who underwent surgery for breast cancer. We estimated the cumul...
Of 153,575 patients, 79,321 received anthracycline-based adjuvant therapy, 14,317 received adjuvant therapy without anthracyclines and 46,657 did not receive adjuvant chemotherapy. Overall, 120 develo...
This study found that anthracycline-based adjuvant therapy significantly increased the risk of AML/MDS in Korean breast cancer patients, with the risk persisting for at least 10 years. While the cumul...
Neuroendocrine neoplasms (NENs) of the breast are rare and not well-studied. NEN are subcategorized as well-differentiated neuroendocrine tumor (NET) and poorly differentiated neuroendocrine carcinoma...
Between 2004 and 2015, 420 NET, 205 NEC, 146 Adenocarcinoma with NE differentiation (ACNED) and 1,479,520 of invasive carcinoma, not otherwise specified (IC-NOS) of the breast were identified in the N...
After adjusting for other prognostic factors, both NET and NEC of the breast showed significantly worse OS than IC-NOS (HR (95% CI) = 1.41 (1.17, 1.72), p = 0.005 and HR (95% CI) = 2.11 (1.67, 2.67), ...
NEN is a unique pathologic and clinical entity, which has worse clinical outcome compared to IC-NOS of the breast. Current therapeutics used in the treatment of IC-NOS improve, but do not fully mitiga...
Breast cancer is the most lethal malignancy for women worldwide. Developed countries, such as Portugal, Spain, and the United States, have declining mortality rates due to breast cancer; however, in d...
Data were obtained from the National Health System Department of Informatics (DATASUS), maintained by the Brazilian Ministry of Health, which includes the registers of hospitalization and mortality by...
From 2008 to 2019, 643,822 hospital admissions due to malignant neoplasm of breast were reported in Brazil, of which the South and Southeast regions were the most prevalent. Higher hospitalization rat...
We have shown an increase in morbidity and mortality over time, which is dependent on patients' age and region. The results presented here may contribute to the ongoing discussion about the role and f...
To explore the differential diagnosis of benign and malignant papillary neoplasms on MRI with non-mass enhancement....
A total of 48 patients with surgically confirmed papillary neoplasms showing non-mass enhancement were included. Clinical findings, mammography and MRI features were retrospectively analyzed, and lesi...
Fifty-three papillary neoplasms were shown on MR images with non-mass enhancement, including 33 intraductal papilloma and 20 papillary carcinomas (9 intraductal papillary carcinoma, 6 solid papillary ...
Papillary carcinoma on MRI with non-mass enhancement mostly showed internal clustered ring enhancement, while papilloma mostly showed internal clumped enhancement; additional mammography is of limited...
Primary neuroendocrine neoplasms of the breast (Br-NENs) are rare. The classification has been updated in recent years making interpretation of the data published challenging. It is unclear whether ne...
The database for breast cancer patients treated between 2009 and 2022 at the Maria Sklodowska-Curie National Research Institute of Oncology Branch Krakow was explored to search for Br-NENs. Patients' ...
We included 22 females with Br-NEN without metastases at the time of diagnosis. The median age was 64 years (range: 28-88), Of the cases, 18 were hormone receptor positive, all were HER-2 negative, th...
Br-NENs represent a heterogenous group of diseases, lacking data from prospective studies or clinical trials. There are no established treatment standards tailored for Br-NENs. Our patients' cohort ex...
We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and ...